We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




MicroRNAs Key Regulators of Blood Cell Development

By LabMedica International staff writers
Posted on 21 Nov 2012
A recent paper on the molecular mechanism that regulates the formation of blood cells demonstrated the importance of microRNA (miRNA) in the control of hematopoietic stem cell (HSC) growth and proliferation.

Hematopoietic stem cells (HSCs) have the unique ability to give rise to all of the different mature blood cell types and tissues. More...
HSCs reside in the bone marrow and are self-renewing. When HSCs proliferate, at least some of their daughter cells remain as HSCs, so the pool of stem cells does not become depleted. The other daughters of HSCs (myeloid and lymphoid progenitor cells) are able to commit to any of the alternative differentiation pathways that lead to the production of one or more specific types of blood cells, but cannot self-renew. The mechanism that determines the fate of HSCs has not been well understood.

Since microRNAs (miRNAs) are now recognized as master controllers of cellular metabolism, investigators at the University of Toronto (Canada) examined their possible role in the regulation of HSC proliferation.

They reported in the November 8, 2012, online edition of the journal Cell Stem Cell that a particular miRNA, miR-126, was a novel regulator of the processes governing HSC quiescence or growth and proliferation. Reduction in miR-126 levels induced an expansion of long-term HSCs without exhaustion, while constitutive miR-126 expression promoted HSC quiescence and the proliferation of myeloid and lymphoid progenitor cells.

“For the first time in human blood stem cells, we have established that a new class of noncoding RNA called miRNA represents a new tactic for manipulating these cells, which opens the door to expanding them for therapeutic uses,” said contributing author Dr. John Dick, professor of molecular genetics at the University of Toronto. “We have shown that if you remove the miRNA you can expand the stem cells while keeping their identity intact. That is the key to long-term stem cell expansion for use with patients.”

Related Links:

University of Toronto




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.